Cell-based therapies for ischemia

Details Cell-based therapies for ischemia Cell-based therapies for ischemia

2004-06-24

2008-12-30

Barnhart, Lora E (Department: 1651)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C424S093700

Reexamination Certificate

active

07470538

ABSTRACT:
The invention provides, among other things, methods for treating an ischemic tissue in a subject in need thereof. The invention further provides methods for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides cell-based formulations and related kits.

REFERENCES:
patent: 4670467 (1987-06-01), Hess et al.
patent: 5486359 (1996-01-01), Caplan et al.
patent: 5591625 (1997-01-01), Gerson et al.
patent: 5612211 (1997-03-01), Wilson et al.
patent: 5652225 (1997-07-01), Isner
patent: 5654186 (1997-08-01), Cerami et al.
patent: 5733542 (1998-03-01), Haynesworth et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5843633 (1998-12-01), Yin et al.
patent: 5980887 (1999-11-01), Isner et al.
patent: 6010696 (2000-01-01), Caplan et al.
patent: 6387367 (2002-05-01), Davis-Sproul et al.
patent: 6387369 (2002-05-01), Pittenger et al.
patent: 6429012 (2002-08-01), Kraus et al.
patent: 6461645 (2002-10-01), Boyse et al.
patent: 6586192 (2003-07-01), Peschle et al.
patent: 6676937 (2004-01-01), Isner et al.
patent: 2001/0051372 (2001-12-01), Yin et al.
patent: 2002/0037278 (2002-03-01), Ueno et al.
patent: 2002/0051762 (2002-05-01), Rafii et al.
patent: 2002/0064519 (2002-05-01), Bruder et al.
patent: 2002/0164794 (2002-11-01), Wernet
patent: 2002/0168765 (2002-11-01), Prockop et al.
patent: 2002/0197240 (2002-12-01), Chiu
patent: 2003/0091547 (2003-05-01), Edelberg et al.
patent: 2003/0148512 (2003-08-01), Fanslow, III et al.
patent: 2003/0148952 (2003-08-01), Crombreholme et al.
patent: 2003/0152558 (2003-08-01), Luft et al.
patent: 2003/0180705 (2003-09-01), Murohara et al.
patent: 2003/0199464 (2003-10-01), Itescu
patent: 2003/0232050 (2003-12-01), Isner et al.
patent: 2004/0131585 (2004-07-01), Itescu
patent: WO 89/03875 (1989-05-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 93/13807 (1993-07-01), None
patent: WO 96/06933 (1996-03-01), None
patent: WO 97/12519 (1997-04-01), None
patent: WO 97/30083 (1997-08-01), None
patent: WO 99/37751 (1999-07-01), None
patent: WO 00/12683 (2000-03-01), None
patent: WO-01/93909 (2001-12-01), None
patent: WO 01/94420 (2001-12-01), None
patent: WO 03/078610 (2003-09-01), None
patent: WO-03/087333 (2003-10-01), None
patent: WO 03/095631 (2003-11-01), None
Osman et al., “Cardiac Cell Transplantation: Closer to Bedside”, Ann Thorac Surg 2003; 75: S674-7.
Minguell et al., “Biology and clinical utilization of mesenchymal progenitor cells”, Braz J Med Biol Res, 2000, 33(3):881-887.
Minguell et al., “Mesenchymal Stem Cells”, Exp Biol Med vol. 226(6):507-520.
Sukhikh et al., “Mesenchymal Stem Cells”, Bulletin of Experimental Biology and Medicine, 2002, 133(2):103-109.
Fibbe et al., “Mesenchymal Stem Cells and Hematopoietic Stem Cell Transplantation”, 2003, Ann. N.Y. Acad Sci, 996:235-244.
Vilkin et al., “Cell Transplantation for Post-Ischemic Heart Failure”, Archives des Maladies du Coeur et des Vaisseaux, 2002, 95(12):1219-1225.
Itescu et al., “Myocardial Neovascularization by Adult Bone Marrow-Derived Angioblasts: Strategies for Improvement of Cardiomyocyte Function”, Ann Hematol. 2002;81 Suppl 2:S21-S25.
Yang et al. Zhonghua Yi Xue Za Zhi, “Transplantation of cord blood endothelial progenitor cells ameliorates limb ischemia” 2003, 83(16) (Abstract).
Erices et al., “Human cord-blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion”, Cell Transplant, 2003, 12(6):555-61.
Rafii et al., “Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration”, Nature Medicine, 2003, 9(3):702-712.
Anker et al., “Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOS/SCID mice”, Exp Hematol. 2003. 31(10).
Rodriguez-Manzaneque et al., “Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor”, PNAS, 2001, 98(22):12485-12490.
Wynter et al., CD34+AC133+ Cells Isolated from Cord Blood are Highly Enriched in Long-Term Culture-Initiating Cells, NOD/SCID-Repopulating Cells and Dendritic Cell Progenitors, Stem Cells, 1998, 16:387-396.
Burt et al., “Hematopoietic stem cell transplantation for cardiac and peripheral vascular disease”, Bone Marrow Transplantation, 2003, 32:S29-S31.
Lazarus et al., “Human Bone Marrow-Derived Mesenchymal (Stomal) Progenitor Cells (MPCs) Cannot Be Recovered from Peripheral Blood Progenitor Cell Collections”, Journal of Hematotherapy, 1997, 6:447-455.
Lazarus et al., “Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use”, Bone Marrow Transplantation, 1995, 16:557-564.
Jaiswal et al., “Osteogenic Differentiation of Purified, Culture-Expanded Human Mesenchymal Stem Cells In Vitro”, Journal of Cellular Biochemistry, 1997, 64:295-312.
Tateishi-Yuyama et al., “Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial”, The Lancet, 2002, 360:427-435.
Koc et al., “Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy”, Journal of Clinical Oncology, 2000, 18(2):307-316.
Ankoma-Sey et al. (1998). “Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing.” Oncogene 17(1): 115-21.
Asahara et al. (1999). “Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.” Circ Res 85(3): 221-28.
Asahara et al.. (1999). “VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.” EMBO J 18(14): 3964-72.
Barry F et al. (2001). “The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells.” Biochem Biophys Res Commun 289(2): 519-24.
Barry FP et al. (1999). “The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105).” Biochem Biophys Res Commun 265(1): 134-9.
Chauhan A et al. (1996). “Aging-associated endothelial dysfunction in humans is reversed by L-arginine.” J Am Coll Cardiol 28(7): 1796-1804.
Cheng T,. (2002). “Cell cycle entry of hematopoietic stem and progenitor cells controlled by distinct cyclin-dependent kinase inhibitors.” Int J Hematol 75(5): 460-5.
D'Apuzzo et al. (1997). “The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4.” Eur J Immunol 27(7): 1788-93.
Fleming et al. (1998). “Monoclonal antibody against adult marrow-derived mesenchymal stem cells recognizes developing vasculature in embryonic human skin.” Dev Dyn 212(1): 119-32.
Gehling et al. (2000). “In vitro differentiation of endothelial cells from AC133-positive progenitor cells.” Blood 95(10): 3106-2.
Gill et al. (2001). “Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells.” Circ Res 88(2): 167-74.
Gu et al. (2000). “Association of extracellular matrix proteins fibulin-1 and fibulin-2 with fibronectin in bone marrow stroma.” Br J Haematol 109(2): 305-13.
Hartlapp et al. (2001). “Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo.” FASEB J 15(12): 2215-24.
Haynesworth et al. (1996). “Cytokine ex

Affiliated with

Also associated with

Rating

Cell-based therapies for ischemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell-based therapies for ischemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-based therapies for ischemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4029659